Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Peikert, A; Solomon, SD.
Contemporary treatment options in heart failure with preserved ejection fraction.
Eur Heart J Cardiovasc Imaging. 2024; 25(11):1517-1524
Doi: 10.1093/ehjci/jeae201
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Peikert Alexander
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Heart failure with preserved ejection fraction (HFpEF) constitutes approximately half of the heart failure population, with its prevalence markedly increasing with older age and the presence of cardio-metabolic comorbidities. Although HFpEF is associated with a high symptom- and mortality burden, historically there have been few evidence-based treatment options for patients with HFpEF. Recent randomized clinical trials have expanded evidence on pharmacological treatment options, introducing new agents for managing HFpEF. Given the complex clinical phenotype with pathophysiological heterogeneity and evolving diagnostic standards, the evidence-based management of HFpEF remains challenging for clinicians. This review summarizes the latest evidence from contemporary randomized clinical trials and recent guideline recommendations to provide guidance for the treatment of patients with HFpEF.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Heart Failure - therapy, physiopathology
- Stroke Volume - physiology
- Aged - administration & dosage
- Female - administration & dosage
- Male - administration & dosage
- Randomized Controlled Trials as Topic - administration & dosage
- Practice Guidelines as Topic - administration & dosage
- Risk Assessment - administration & dosage
- Prognosis - administration & dosage
- Find related publications in this database (Keywords)
- heart failure with preserved ejection fraction
- guideline-directed medical therapeutics